Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial-Reference-Cited by-同舟云学术

Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial

Published:2020-03 Issue:10 Volume:75 Page:1145-1155
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Zeitouni Michel,Giczewska Anna,Lopes Renato D.,Wojdyla Daniel M.,Christersson Christina,Siegbahn Agneta,De Caterina Raffaele,Steg Philippe Gabriel,Granger Christopher B.,Wallentin Lars,Alexander John H.

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society;January;J Am Coll Cardiol,2014

2. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

3. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS;Kirchhof;Eur Heart J,2016

4. Apixaban versus Warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011

5. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation;British Journal of Clinical Pharmacology;2024-08-15

2. Perils of reduced dose apixaban in atrial fibrillation/flutter – A case report with a brief literature review;The American Journal of the Medical Sciences;2024-08

3. Letter by Millis et al Regarding Article, “Safety of Switching From a Vitamin K Antagonist to a Non–Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial”;Circulation;2024-07-09

4. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study;Blood Advances;2024-04-10

5. Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants;Therapeutic Advances in Cardiovascular Disease;2024-01